IDEXX Expands Fecal Dx® Antigen Testing Platform with Cystoisospora Detection, Marking the Second Platform Expansion in Less than Two Years

Fecal Dx antigen testing will soon detect the most common intestinal parasites earlier, uncovering more infections

WESTBROOK, Maine, Jan. 12, 2024 /PRNewswire/ — IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the expansion of its Fecal Dx^® antigen testing platform with the addition of Cystoisospora, a common intestinal parasite that causes diarrhea, weight loss, and dehydration, primarily in young dogs and cats. IDEXX’s Fecal Dx antigen testing offers earlier and highly accurate detection of the most common and clinically relevant intestinal parasites of dogs and cats: hookworms, roundworms, whipworms, flea tapeworms, and soon Cystoisospora. The launch of Fecal Dx antigen testing with Cystoisospora is planned for March in North America and globally in Q3 2024, available at IDEXX Reference Laboratories.

Read more at prnewswire.com